Bannerbild German Brest Group - Forschung

Overview of congress submissions from 2013

The following submissions were presented at international congresses in 2013 by members of the German Breast Group:

San Antonio Breast Cancer Conference

Loibl S, Denkert C, Schneeweis A, Paepke S, Lehmann A, Rezai M, Zahm D-M, Sinn P, Khandan F, Eidtmann H, Dohnal K, Huober J, Loi S, Pfitzner B, Fasching PA, Andre F, Lindner J, Sotiriou C, Guo S, Gade S, Nekljudova V, Untch M, von Minckwitz G: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. (presentation)

von Minckwitz G, Rezai M, Eidtmann H, Tesch H, Huober J, Gerber B, Zahn DM, Costa S, Gnant M, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Fasching PA, Schneeweiss A, Paepke S, Untch M, Nekljudova V, Mehta K, Loibl S: NATAN slide presentation Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBG 36/ABCSG XX). (presentation)

Denkert C, Loibl S, Salat C, Sinn BV, Schem C, Endris V, Klare P, Schmitt WD, Blohmer J-U, Weichert W, Tesch H, Darb-Esfahani S, Kümmel S, Sinn P, Stenzinger A, Jackisch C, Dietel M, Reimer T, Loi S, Mehta K, Gade S, Untch M, von Minckwitz G: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). (presentation)

Cuzick J, Sestak I, Forbes JF, Cawthorn S, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, Knox J, Dowsett M, Saunders C: First results of the International breast cancer intervention study II (IBIS-II): A multicentre prevention trial of anastrozole versus placebo in postmenopausal women at increased risk of developing breast cancer. (presentation)

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Brown DN, Kellokumpu-Lehtinen P-L, Bono P, Kataja V, Desmedt C, Piccart-Gebhart MJ, Loibl S, Untch M, Denkert C, Smyth MJ, Joensuu H, Sotiriou C: 05. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). (presentation)

Fontanella C, von Minckwitz G, Mergler B, Neven P, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Vanoppen M, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Jackisch C, Keyur M, Nekljudova V, Untch M, Loibl S: Body mass index (BMI) and treatment outcome of breast cancer patients receiving neoadjuvant therapy (NACT). (poster discussion)

von Minckwitz G, Bear H, Bonnefoi H, Colleoni M, Gelmon K, Gnant M, Kim S-B, Loibl S, Makris A, Martin M, Nekljudova V, Rugo H, Saini KS, Toi M, Untch M, Werutsky G. German Breast Group: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13). (poster presentation)

von Minckwitz G, Kern P, Schneeweiss A, Gluz O, Harbeck N, Neumann M, Badiian M, Fries H, Rezai M: Features of neoadjuvant and adjuvant chemotherapy in breast cancer – A population-based study on 39404 patients. (poster presentation)

Geyer CE, Loibl S, Mamounas EP, Untch M, Wolmark N, Huang C-S, Mano M, Zheng M, Smitt M, von Minckwitz G: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE). (poster presentation)

Loibl S, Mergler B, Eppel A, Solbach C, Lübbe KM, Eidtmann H, Rezai M, Hanusch C, Fehm T, Bartzke G, Burgmann D-M, Krabisch P, Untch M, Nekljudova V, von Minckwitz G: The choice of the indicator lesion impacts on the pCR rate – An analysis of 114 bilateral breast cancer patients treated within neoadjuvant trials. (poster presentation)

Loi S, Loibl S, Di Cosimo S, Nekljudova V, Flamen P, Saini KS, Michiels S, de la Pena L, Nanni S, Urban P, Piccart M, Von Minckwitz G, Baselga J: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE. (poster presentation)

ECCO / ESMO

Loibl S, De la Haba J, von Minckwitz F, Morales S, Crespo C, Antón A, Carrasco E, Aktas B, Mehta K, Martin M on behalf of GEICAM and GBG: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - Final Analysis LEA study.

ASCO

von Minckwitz G, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, Tesch H, Khandan F, Jud S, Jackisch C, Mehta K, Loibl S, Untch M, German Breast Group: A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 31, 2013 (suppl; abstr 1004)

Loibl S, Denkert C, Loi S, Andre F, Mueller B, Schneeweiss A, Blohmer JU, Jackisch C, Sanxing G, Gade S, Fasching PA, Schem C, Sotiriou C, Untch M, von Minckwitz G, German Breast Group: PIK3CA mutations in primary HER2-positive and triple negative breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 11061)

Lueck HJ, Luebbe K, Bischoff J, Maass N, Feisel G, Tome O, Janni W, Aydogdu M, Neuhoeffer T, Ober A, Aktas B, Park-Simon TW, Schumacher C, Hoeffkes HG, Illmer T, Wagner H, Mehta K, Nekljudova V, Loibl S, von Minckwitz G, German Breast Group: A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 1082)

Jackisch C, Wiebringhaus F, Conrad B, Weigel M, Aktas B, Wagner H, Latos K, Kohls A, Bueckner U, Hauzenberger T, Bangemann N, Hackmann J, Clemens MR, Heinrich B, Tome O, Loibl S, Nekljudova V, von Minckwitz G, German Breast Group: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69. J Clin Oncol 31, 2013 (suppl; abstr TPS1141)

Moebus V, Forstbauer H, Wachsmann G, Schneeweiss A, Ober A, von Abel E, Krabisch P, Hoeffkes HG, Kast K, Christensen B, Niedermeier M, Deryal M, Uleer C, Fauster I, Goehler T, Loibl S, Nekljudova V, von Minckwitz G, German Breast Group: Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2). J Clin Oncol 31, 2013 (suppl; abstr TPS1137)

Paepke S, Kümmel S, Blohmer JU, Costa SD, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober JB, Jackisch C, Schneeweiss A, Denkert C, Mehta K, Loibl S, von Minckwitz G, German Breast Group: Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal b/HER2 normal breast cancer (GENEVIEVE). J Clin Oncol 31, 2013 (suppl; abstr TPS1138)

Michiels S, Pugliano L, Grun D, Barinoff J, Cameron DA, Cobleigh MA, Di Leo A, Johnston SRD, Gasparini G, Kaufman B, Marty ME, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon DJ, Vogel CL, von Minckwitz G, Buyse ME, Piccart-Gebhart MJ: Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. J Clin Oncol 31, 2013 (suppl; abstr 610)

Liedtke C, Goerlich D, Van Zee KJ, Korndoerfer J, Bauerfeind I, Fehm TN, Fleige B, Helms G, Annette Lebeau, Mai M, Staebler A, von Minckwitz G, Untch M, Kühn T: Predicting nonsentinel lymph node metastases using established nomograms among patients with breast cancer after primary systemic therapy (PST): The transSENTINA substudy. J Clin Oncol 31, 2013 (suppl; abstr 1020)

St. Gallen Congress

Untch M, Loibl S, Jackisch C, Wiebringhaus H, Forstbauer H, Wachsmann G, Zofia Maczynska, Valentina Nekljudova, Gunter von Minckwitz, Volker Möbus: Safety of 150mg/m²nab-paclitaxel weekly either as weekly or as 300mg/m² biweekly regimen. Poster presentation (Poster # 249) at St. Gallen Congress 2013

AACR

von Minckwitz G, Mamouhdian-Dekordi C, Loibl S, Blohmer J-U, Costa S, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Mehta K, Untch M, Jackisch C: Response characteristics and overall survival of 781 patients with triple-negative breast cancer – a meta-analysis on 7 German neoadjuvant studies. Poster presentation (Poster # 1195) AACR in Washington, 2013

Loibl S, Denkert C, Loi S, Andre F, Schneeweiss A, Blohmer J, Jackisch C, Gade S, Fasching P, Schem C, Sotiriou C, Untch M, von Minckwitz G: PIK3CA mutations in primary HER2-positive and triple negative breast cancer. Poster presentation (Poster # 1220) at AACR in Washington, 2013

Contact

Hilal Gökgöz

Phone: +4961027480-223

Fax: +4961027480-129

E-Mail: Publication@gbg.de

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd